Cargando…

ImmunoPET in Multiple Myeloma—What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Clément, Chalopin, Benjamin, Gouard, Sébastien, Carlier, Thomas, Remaud-Le Saëc, Patricia, Marionneau-Lambot, Séverine, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodere, Françoise, Bodet-Milin, Caroline, Chérel, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://www.ncbi.nlm.nih.gov/pubmed/32512883
http://dx.doi.org/10.3390/cancers12061467
_version_ 1783557770496180224
author Bailly, Clément
Chalopin, Benjamin
Gouard, Sébastien
Carlier, Thomas
Remaud-Le Saëc, Patricia
Marionneau-Lambot, Séverine
Moreau, Philippe
Touzeau, Cyrille
Kraeber-Bodere, Françoise
Bodet-Milin, Caroline
Chérel, Michel
author_facet Bailly, Clément
Chalopin, Benjamin
Gouard, Sébastien
Carlier, Thomas
Remaud-Le Saëc, Patricia
Marionneau-Lambot, Séverine
Moreau, Philippe
Touzeau, Cyrille
Kraeber-Bodere, Françoise
Bodet-Milin, Caroline
Chérel, Michel
author_sort Bailly, Clément
collection PubMed
description Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint inhibitors) appears to have changed the paradigm of MM management, emphasizing the opportunity to cure MM patients through an immunotherapeutic approach. In this context, immuno-positron emission tomography (immunoPET), combining the high sensitivity and resolution of a PET camera with the specificity of a radiolabelled mAb, holds the capability to cement this new treatment paradigm for MM patients. It has the potential to non-invasively monitor the distribution of therapeutic antibodies or directly monitor biomarkers on MM cells, and to allow direct observation of potential changes over time and in response to various therapeutic interventions. Tumor response could, in the future, be anticipated more effectively to provide individualized treatment plans tailored to patients according to their unique imaging signatures. This work explores the important role played by immunotherapeutics in the management of MM, and focuses on some of the challenges for this drug class and the significant interest of companion imaging agents such as immunoPET.
format Online
Article
Text
id pubmed-7352991
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73529912020-07-15 ImmunoPET in Multiple Myeloma—What? So What? Now What? Bailly, Clément Chalopin, Benjamin Gouard, Sébastien Carlier, Thomas Remaud-Le Saëc, Patricia Marionneau-Lambot, Séverine Moreau, Philippe Touzeau, Cyrille Kraeber-Bodere, Françoise Bodet-Milin, Caroline Chérel, Michel Cancers (Basel) Perspective Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint inhibitors) appears to have changed the paradigm of MM management, emphasizing the opportunity to cure MM patients through an immunotherapeutic approach. In this context, immuno-positron emission tomography (immunoPET), combining the high sensitivity and resolution of a PET camera with the specificity of a radiolabelled mAb, holds the capability to cement this new treatment paradigm for MM patients. It has the potential to non-invasively monitor the distribution of therapeutic antibodies or directly monitor biomarkers on MM cells, and to allow direct observation of potential changes over time and in response to various therapeutic interventions. Tumor response could, in the future, be anticipated more effectively to provide individualized treatment plans tailored to patients according to their unique imaging signatures. This work explores the important role played by immunotherapeutics in the management of MM, and focuses on some of the challenges for this drug class and the significant interest of companion imaging agents such as immunoPET. MDPI 2020-06-04 /pmc/articles/PMC7352991/ /pubmed/32512883 http://dx.doi.org/10.3390/cancers12061467 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Bailly, Clément
Chalopin, Benjamin
Gouard, Sébastien
Carlier, Thomas
Remaud-Le Saëc, Patricia
Marionneau-Lambot, Séverine
Moreau, Philippe
Touzeau, Cyrille
Kraeber-Bodere, Françoise
Bodet-Milin, Caroline
Chérel, Michel
ImmunoPET in Multiple Myeloma—What? So What? Now What?
title ImmunoPET in Multiple Myeloma—What? So What? Now What?
title_full ImmunoPET in Multiple Myeloma—What? So What? Now What?
title_fullStr ImmunoPET in Multiple Myeloma—What? So What? Now What?
title_full_unstemmed ImmunoPET in Multiple Myeloma—What? So What? Now What?
title_short ImmunoPET in Multiple Myeloma—What? So What? Now What?
title_sort immunopet in multiple myeloma—what? so what? now what?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://www.ncbi.nlm.nih.gov/pubmed/32512883
http://dx.doi.org/10.3390/cancers12061467
work_keys_str_mv AT baillyclement immunopetinmultiplemyelomawhatsowhatnowwhat
AT chalopinbenjamin immunopetinmultiplemyelomawhatsowhatnowwhat
AT gouardsebastien immunopetinmultiplemyelomawhatsowhatnowwhat
AT carlierthomas immunopetinmultiplemyelomawhatsowhatnowwhat
AT remaudlesaecpatricia immunopetinmultiplemyelomawhatsowhatnowwhat
AT marionneaulambotseverine immunopetinmultiplemyelomawhatsowhatnowwhat
AT moreauphilippe immunopetinmultiplemyelomawhatsowhatnowwhat
AT touzeaucyrille immunopetinmultiplemyelomawhatsowhatnowwhat
AT kraeberboderefrancoise immunopetinmultiplemyelomawhatsowhatnowwhat
AT bodetmilincaroline immunopetinmultiplemyelomawhatsowhatnowwhat
AT cherelmichel immunopetinmultiplemyelomawhatsowhatnowwhat